Eagle Health Investments’s Ascendis Pharma A/S ASND Stock Holding History

Eagle Health Investments’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.3M	Buy	106,158 +19,508	+23%	+$4.56M	4.69%	11
2026 Q1	$19.8M	Buy	+86,650	New	+$19.4M	3.47%	12
2025 Q2	–	Sell	-56,500	Closed	-$8.81M	–	22
2025 Q1	$8.81M	Buy	+56,500	New	+$8.07M	2.29%	16

Other funds holding ASND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Eagle Health Investments's ASND Position: Q2 2026 in Review

Eagle Health Investments increased its Ascendis Pharma A/S (ASND) stake by 23% in Q2 2026, buying an estimated $4.56M and bringing the position to 106,158 shares worth $28.3M. The position accounts for 4.69% of the portfolio, ranked #11.

Eagle Health Investments first reported a position in ASND in Q1 2025 and has held it in 3 quarters since. 116 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Eagle Health Investments held 106,158 shares of Ascendis Pharma A/S worth $28.3M as of Q2 2026.
Eagle Health Investments bought 19,508 Ascendis Pharma A/S shares in Q2 2026, an estimated $4.56M.
Ascendis Pharma A/S made up 4.69% of Eagle Health Investments's portfolio in Q2 2026, its #11 holding.
Eagle Health Investments first reported a position in Ascendis Pharma A/S in Q1 2025 and has held it in 3 quarters since.
116 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Eagle Health Investments's 13F filing for Q2 2026, filed 10 Aug 2026.